Peter van der Heyden

Peter van der Heyden has extensive experience in the pharmaceutical industry, particularly in the field of psychedelic drug substances and products. Peter currently serves as the Chief Science Officer at Psygen Labs Inc., where they focus on research related to the chemistry, synthesis, and therapeutic applications of lysergamides and tryptamines. Peter is actively involved in the cGMP manufacture of classical psychedelics for clinical trials and explores biotechnological research for the development of novel psychedelic drug molecules. Prior to their current role, they were the Chief Executive Officer at PsyGen Inc., overseeing the manufacturing and formulation of cGMP psychedelic drug substances for use in clinical trials. Before their involvement in the psychedelic industry, van der Heyden served as the CEO of Aurora Bioanalytical Inc. for over 13 years.

Peter van der Heyden attended The University of British Columbia from 1977 to 1989, where they obtained a Doctor of Philosophy - PhD degree. The field of study is unknown.